Exelixis (FRA:EX9) Cyclically Adjusted Book per Share: €5.70 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EX9 Exelixis Inc FRA:EX9
90 GF Score
Price €46.16
GF Value €40.66
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Cyclically Adjusted Book per Share?

Exelixis FRA:EX9 +3.50% 90 Cyclically Adjusted Book per Share is €5.70 as of Jun. 2026. GuruFocus rates FRA:EX9 with a GF Score™ of 90/100 and a GF Value™ of €40.66 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Exelixis's adjusted book value per share for the three months ended in Jun. 2026 was €6.430. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €5.70 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Exelixis's average Cyclically Adjusted Book Growth Rate was 19.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 22.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 28.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Exelixis was 179.80% per year. The lowest was -88.20% per year. And the median was 24.30% per year.

As of today (2026-08-20), Exelixis's current stock price is €46.16. Exelixis's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €5.70. Exelixis's Cyclically Adjusted PB Ratio of today is 8.10.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Exelixis was 223.00. The lowest was 4.94. And the median was 7.86.


Exelixis  (FRA:EX9) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Exelixis's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=46.16/5.70
=8.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Exelixis was 223.00. The lowest was 4.94. And the median was 7.86.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Exelixis Cyclically Adjusted Book per Share Related Terms


Exelixis Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Exelixis's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis Cyclically Adjusted Book per Share Chart

Exelixis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.24 2.86 3.53 4.64 5.07

Exelixis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 4.66 5.07 5.33 5.70

FRA:EX9 vs MDGL, AXSM, ARWR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted PB Ratio falls into.


FRA:EX9
90GF Score
Exelixis Inc FRA:EX9
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exelixis Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Exelixis's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.43/333.9520*333.9520
=6.430

Current CPI (Jun. 2026) = 333.9520.

Exelixis Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.100 241.428 0.138
201612 0.292 241.432 0.404
201703 0.383 243.801 0.525
201706 0.450 244.955 0.613
201709 0.677 246.819 0.916
201712 0.813 246.524 1.101
201803 1.831 249.554 2.450
201806 2.227 251.989 2.951
201809 2.626 252.439 3.474
201812 3.774 251.233 5.017
201903 4.065 254.202 5.340
201906 4.351 256.143 5.673
201909 4.794 256.759 6.235
201912 4.978 256.974 6.469
202003 5.172 258.115 6.692
202006 5.271 257.797 6.828
202009 5.082 260.280 6.520
202012 4.957 260.474 6.355
202103 5.125 264.877 6.462
202106 5.386 271.696 6.620
202109 5.677 274.310 6.911
202112 6.136 278.802 7.350
202203 6.503 287.504 7.554
202206 7.030 296.311 7.923
202209 7.802 296.808 8.778
202212 7.251 296.797 8.159
202303 7.343 301.836 8.124
202306 7.286 305.109 7.975
202309 7.074 307.789 7.675
202312 6.856 306.746 7.464
202403 6.636 312.332 7.095
202406 6.904 314.175 7.339
202409 7.174 315.301 7.598
202412 7.607 315.605 8.049
202503 7.153 319.799 7.470
202506 6.527 322.561 6.757
202509 6.867 324.800 7.060
202512 7.032 324.054 7.247
202603 6.600 330.213 6.675
202606 6.430 333.952 6.430

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €5.70 mean?
Exelixis (FRA:EX9) has a Cyclically Adjusted Book per Share of €5.70 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Exelixis and its competitors.
Is Exelixis' Cyclically Adjusted Book per Share too high?
Exelixis' current Cyclically Adjusted Book per Share is €5.70. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Cyclically Adjusted Book per Share compare to MDGL and AXSM?
Exelixis' Cyclically Adjusted Book per Share of €5.70 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Exelixis and its competitors. Exelixis's current Cyclically Adjusted Book per Share is €5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current Cyclically Adjusted Book per Share is €5.70. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current Cyclically Adjusted Book per Share is €5.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exelixis (FRA:EX9) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for FRA:EX9:

  • Cyclically Adjusted Book per Share: €5.70
  • GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score

Get the complete analysis for FRA:EX9

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.16
Price
€40.66
GF Value